Your Messages Inbox
Your Article Summary
See Latest ArticlesColorectal Cancer Drugs Require Careful Patient Selection
National Cancer Institute, 06/24/08
Patients with advanced colorectal cancer who have mutant forms of the gene KRAS in their tumors should not receive chemotherapy plus cetuximab (Erbitux), because they are unlikely to benefit from the treatment and should be spared the side effects and cost. An estimated 30 to 40 percent of colorectal tumors carry KRAS mutations, and commercial tests are available. Screening could proceed based on the breast cancer model, where women undergo testing for genetic characteristics of their tumors prior to treatment with trastuzumab.
Related Articles
Colorectal cancer incidence and postmenopausal hormone use by type, recency, and duration in cancer prevention study II
Cancer Epidemiology, Biomarkers & Prevention, 10/28/09
Relevance Score: 72%
Association of IGF1 and IGFBP3 polymorphisms with colorectal polyps and colorectal cancer risk
Cancer Causes and Control, 10/02/09
Relevance Score: 72%
P73 expression and its clinical significance in colorectal cancer
Colorectal Disease, 10/19/09
Relevance Score: 71%
trans-Fatty acid consumption and its association with distal colorectal cancer in the North Carolina Colon Cancer Study II
Cancer Causes and Control, 10/28/09
Relevance Score: 70%
Association of clinicopathological features with UbcH10 expression in colorectal cancer
Journal of Cancer Research & Clinical Oncology, 10/01/09
Relevance Score: 70%
Today in Physician/Patient Trends...keeping you current
Receive free subspecialty "5-minute updates" via email
Trends in hypertension treatment in diabetes
Current Hypertension Reports, 12/09/09
New program helps educate survivors of a heart event about the importance of maintaining good physical and emotional health
Daiichi Sankyo, 12/08/09
Surgical and minimally invasive treatments for Peyronie's disease
Current Opinion in Urology, 11/19/09
Article Search
Sponsor